Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase EARLY_PHASE1 1

Status

Withdrawn 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 407Gynecologic 50Genitourinary 6Thoracic 5Sarcoma 5Tumor-Agnostic 4Other solid neoplasm 4Gastrointestinal 4Other 3Lymphoid 2Head & Neck 2Endocrine 2CNS 1

Conditions

Prostatic Neoplasms 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Breast Neoplasms 2Sarcoma 1Liposarcoma 1Fibrolamellar hepatocellular carcinoma 1Colorectal Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 325Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Letrozole × Gastrointestinal × Clear all
NCT06630325 2026-04-28

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
6 enrolled 3 charts
GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04557449 2025-10-01

CDK4i

Pfizer

Phase 2 Active not recruiting
362 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT01642186 2022-12-29

Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
28 enrolled 13 charts
Gastrointestinal

Fibrolamellar hepatocellular carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡